| Oct 31 |
Travere Therapeutics Reports Third Quarter 2024 Financial Results
|
| Oct 30 |
A Preview Of Travere Therapeutics's Earnings
|
| Oct 30 |
Travere Therapeutics Q3 2024 Earnings Preview
|
| Oct 28 |
Travere presents data reinforcing clinical benefit of FILSPARI in IgAN
|
| Oct 26 |
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
|
| Oct 21 |
Travere Therapeutics to Report Third Quarter 2024 Financial Results
|
| Oct 17 |
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
|
| Oct 17 |
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
|
| Oct 14 |
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
|
| Oct 10 |
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
|
